Liu Hesheng, a professor at Changping Laboratory and senior author of the study, said that as of late November, more than 100 patients in China and abroad have been treated with the device.

One patient, an elderly woman surnamed Hu, saw fewer falls and improvements in independent walking, swallowing, and speech after just one course of treatment. After three years of biannual sessions, she has reduced her medication by more than half, significantly lowered her risk of motor complications, and regained the ability to manage daily activities independently. She is now considering traveling abroad.

Liu stressed the importance of early intervention in neurodegenerative diseases before extensive neuron loss makes recovery unlikely.

“While patients may hesitate to undergo invasive surgery in the early stages, this noninvasive therapy offers a viable option to intervene earlier and more precisely,” he said.

Ren Jianxun, a scientist at Changping Laboratory and first author of the study, added that the device has already received a Class 2 medical device registration license. “We aim to obtain the highest Class 3 certification by conducting further clinical trials in the coming years,” he said.